HOTLINE 24/7/365 UK: +44 (0) 1483 212150

Global Locations

PharSafer® report to the countries listed below on behalf of our current clients, however, this is not an exhaustive list of our reporting experience capabilities:

Afghanistan; Algeria; Antigua and Barbuda; Albania; Armenia; Argentina; Austria; Australia; Azerbaijan; Bosnia and Herzegovina; Barbados; Bangladesh; Belgium; Bulgaria; Bermuda; Brazil; Bahamas; Belarus; Canada; Chile; China; Colombia; Costa Rica; Croatia (Hrvatska); Cuba; Cyprus; Czech Republic; Denmark; Ecuador; El Salvador; Equatorial Guinea; Estonia; Egypt; Finland; France; Gambia; Germany; Georgia; Gibraltar; Greece; Hong Kong; Honduras; Haiti; Hungary; Indonesia; Ireland; Israel; India; Iraq; Iran; Iceland; Italy; Jamaica; Jordan; Japan; Kenya; Korea (South); Liechtenstein; Lithuania; Luxembourg; Latvia; Libya; Macedonia; Malaysia; Malta; Mauritius; Mexico; Micronesia; Morocco; Monaco; Moldova; Netherlands; Norway; New Zealand; Oman; Peru; Pakistan; Poland; Portugal; Paraguay; Qatar; Romania; Russia; Saudi Arabia; Sweden; Singapore; Slovenia; Slovak Republic; South Africa; S. Georgia and S.sandwich Isls; Spain; Sri Lanka; Switzerland; Tunisia; Turkey; Taiwan; Ukraine; United Arab Emirates; United Kingdom; United States; Uruguay; Uzbekistan; Venezuela; Viet Nam.

Note: We have experience in the safety reporting rules for many more countries than those listed above, for drugs, devices, biologics, cosmetics, compassionate use, biosimilars, vaccines and advanced therapies for both clinical trial and post-marketing situations.

Current global offices include the United Kingdom, USA, Middle East and India:

pharsafer-house72500x333-1-w640-2PharSafer House, Ripley, United Kingdom, is the Global Operations Centre for the group. It acts as the central communications hub where all activities are quality assessed before sending to clients or Regulatory Agencies. These purpose built offices were opened in 2012 and operate 24/7, with a team of experts on-hand to respond to scheduled client enquiries as well as urgent and often critical, time sensitive issues.

PharSafer® Tweets

The Medicines and Healthcare products Regulatory Agency (MHRA) has signed a Memorandum of Understanding (MoU) with… t.co/gXZX2QSDt7

Read on Twitter...

Draft guidance surrounding the key principles of Electronic Product Information was published as a joint EMA-HMA-EC… t.co/ljDu4QBpag

Read on Twitter...

Brand new public consultation launched today: the European Medicines Agency (EMA), in collaboration with the Heads… t.co/UqOCdfN3LF

Read on Twitter...